At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 42 enrolled
Drug / intervention
AMG 224drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects With Relapsed or Refractory Multiple Myeloma
In Brief
A Phase 1 clinical trial evaluating AMG 224 for Multiple Myeloma. Completed, enrolled 42 participants across 5 sites in 2 countries.
Detailed Summary
This is a first in human phase 1 multicenter open label study in subjects with relapsed or refractory multiple myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesAustralia, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartNov 2015
Primary CompletionNov 2018
Study CompletionApr 2022
TodayJul 2026
First PostedSep 28, 2015
Enrollment StartNov 20, 2015
Primary CompletionNov 30, 2018
Study CompletionApr 21, 2022
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 10.8 years ago
Interventions
AMG 224drug
Administered as an IV infusion.